BEVERLY HILLS, Calif.--(BUSINESS WIRE)--Nov. 18, 2003--Vencor International (Pink Sheets:VNCO - News), an emerging manufacturer and distributor of molecular diagnostics technologies and invitro point-of-care rapid diagnostic tests that identify diseases, announced today that it has retained the Investor and Public Relations services of STAR Capital Inc. "STAR Capital Inc. has a national reputation for delivering premier Investor Relations services, critical to our success," states Vencor VP Operations Ben Armijo.
"Vencor International has an outstanding product that not only serves to provide shareholders with the potential for positive growth, but is critical in the identification and prevention of disease. This is the type of company we can all feel good about," states Mark Yamazaki of STAR Capital.
STAR Capital Inc. is a full service Venture Capital and Investor Relations firm. STAR Capital maintains offices in Calgary, Alberta. www.vcir.com
Vencor International is a global manufacturer and distributor of molecular diagnostics technologies and invitro point-of-care rapid diagnostic tests that identify diseases. Vencor distributes the AccuDx line of products including the AccuSpot(TM) Dengue Fever-IgG & IgM Rapid Test, AccuDx'DxStrip HIV Rapid Test, DxStrip Malaria Combo Rapid Test and others. www.vencorinternational.com
Safe Harbor Statement
The information contained in this press release, including "forward-looking statements" within section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 contained herein, should be reviewed in conjunction with the company's annual report, financial filings and other publicly available information regarding the company, copies of which are available from the company upon request. Such publicly available information sets forth many risks and uncertainties related to the Company's business, and such statements, including risks and uncertainties related to that, are unpredictable and outside of the influence and/or control of the company.
Vencor International, Inc. Mark Yamazaki, 310-289-3488 (investor relations) email@example.com
Source: Vencor International, Inc.